Biotech Values

[WorstLuck]

Ocular Therapeutix™ to Present Detailed SOL-1 Data at the 49th Macula Society Annual Meeting and Host Investor Webcast to Discuss Presentations
February 23, 2026
PDF Version
Ocular to present detailed SOL-1 data at the 49th Macula Society Annual Meeting on Friday, February 27, 2026, starting at 1:00 PM PT (4:00 PM ET)

Company to host an investor webcast on Monday, March 2, 2026, at 7:30 AM ET to discuss the Macula Society presentations

BEDFORD, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that the Company will present detailed results from the SOL-1 Phase 3 superiority clinical trial of AXPAXLI™ (also known as OTX-TKI), for the treatment of wet age-related macular degeneration (wet AMD), at the 49th Macula Society Annual Meeting on Friday, February 27, 2026, with data presentations starting at 1:00 PM PT (4:00 PM ET). Ocular plans to host an investor webcast on Monday, March 2, 2026, at 7:30 AM ET to discuss the Macula Society presentations.

https://investors.ocutx.com/news-releases/news-release-details/ocular-therapeutixtm-present-detailed-sol-1-data-49th-macula

The SOL-1 Symposium slides will be made available by a Current Report on Form 8-K to be furnished to the Securities and Exchange Commission (SEC) at 4:00 PM ET on Friday, February 27, 2026. Ocular also plans to make a copy of all slides presented at the 49th Macula Society Annual Meeting available on its website.